Actively Recruiting

Age: 18Years +
FEMALE
ID05763511

Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker

Led by University of Aarhus · Updated on 2024-05-09

300

Participants Needed

1

Research Sites

230 weeks

Total Duration

On this page

Sponsors

U

University of Aarhus

Lead Sponsor

A

Aarhus University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to improve the diagnosis of ovarian cancer in women who have suspected ovarian tumors. The study focuses on measuring circulating tumor DNA (ctDNA) to help distinguish between benign and malignant masses before surgery. Researchers also plan to explore how ctDNA relates to tumor type, stage, treatment response, and prognosis, aiming to develop a better diagnostic approach. Women participating in the study will have blood and tumor tissue samples collected, along with data from imaging tests such as ultrasonography, MRI, and PET-CT, as well as CA 125 blood tests. These samples and data will be gathered prospectively from patients referred to Aarhus University Hospital for suspected ovarian masses. Participants will be involved in various assessments including the analysis of ctDNA and imaging results to evaluate diagnostic accuracy compared to histopathological diagnosis. The study will also monitor disease stage, treatment response, survival rates, and tumor biology over time. The primary outcome will be measured within 6 months, with treatment response and survival tracked for up to 2 and 5 years respectively.

CONDITIONS

Brief Title

Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Suspected ovarian neoplasm
  • Able to provide informed consent
  • Female
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Previous diagnosis of ovarian cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 6 months

Participants undergo diagnostic procedures including blood tests for circulating tumor DNA and imaging scans to help differentiate ovarian masses.

Multiple visits depending on diagnostic procedures

Long-term Monitoring

Duration - Up to 5 years

Participants are monitored for treatment response, disease progression, and survival over time.

Periodic visits for assessments up to 5 years

Trial Site Locations

Total: 1 location

1

Department of Gynaecology and Obstetrics, Aarhus University Hospital

Aarhus, Denmark

Actively Recruiting

Loading map...

Research Team

I

Ina Marie Dueholm Hjorth, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirum...

Ovarian Neoplasms

Actively Recruiting

89 locations

A Cohort Study of Hereditary Ovarian Cancer Risk Prediction ...

Ovarian Neoplasms

Actively Recruiting

1 location

Validation of CleoDX Ovarian Adnexal Mass Assessment Score T...

Ovarian Neoplasms

Actively Recruiting

8 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here